Achieve Life Sciences (ACHV) Cash & Equivalents (2010 - 2026)

Achieve Life Sciences (ACHV) has 17 years of Cash & Equivalents data on file, last reported at $29.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 125.11% year-over-year to $29.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.3 million (up 125.11% YoY) and the FY2025 annual result came in at $36.4 million, up 185.42% from the prior year.
• Cash & Equivalents declined to $29.3 million in Q1 2026, from $36.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $66.4 million in Q1 2024 to a low of $9.5 million in Q3 2024.
• A 5-year average of $27.2 million and a median of $24.8 million in 2022 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 403.98% in 2025, down 80.4% in 2025.
• Tracing ACHV's Cash & Equivalents over 5 years: stood at $24.8 million in 2022, then slumped by 42.46% to $14.3 million in 2023, then dropped by 10.52% to $12.8 million in 2024, then soared by 185.42% to $36.4 million in 2025, then slipped by 19.51% to $29.3 million in 2026.
• The last three Cash & Equivalents figures came in at $29.3 million (Q1 2026), $36.4 million (Q4 2025), and $48.1 million (Q3 2025), per Business Quant data.